Back to top
more

Biohaven Ltd. (BHVN)

(Delayed Data from NYSE)

$38.97 USD

38.97
946,671

+0.43 (1.12%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $38.98 +0.01 (0.03%) 7:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BHVN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Biohaven Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 382 501 365 355 317
Receivables 13 46 308 120 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 81 40 0
Other Current Assets 47 40 123 88 12
Total Current Assets 442 587 876 603 328
Net Property & Equipment 17 18 15 9 8
Investments & Advances 0 0 0 1 5
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 20 20 56 39 0
Deposits & Other Assets 34 38 130 34 2
Total Assets 513 662 1,077 687 344
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 16 11 52 48 14
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 40 44 420 166 52
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 35 63 63 0
Total Current Liabilities 55 90 534 277 66
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 627 267 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 2 659 535 286
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 85 123 1,820 1,079 352
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 888 616 1,677 1,250 881
Capital Surplus 40 14 170 99 84
Retained Earnings -499 -91 -2,586 -1,739 -972
Other Equity 0 0 -4 -2 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 428 539 -743 -392 -7
Total Liabilities & Shareholder's Equity 513 662 1,077 687 344
Total Common Equity 428 539 -743 -392 -7
Shares Outstanding 80.20 68.10 65.50 59.90 52.20
Book Value Per Share 5.34 7.91 -11.34 -6.55 -0.14

Fiscal Year End for Biohaven Ltd falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 382 241 376 450
Receivables NA 13 13 9 44
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 47 57 50 51
Total Current Assets NA 442 311 434 544
Net Property & Equipment NA 17 18 17 17
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 20 20 20 20
Deposits & Other Assets NA 34 35 36 37
Total Assets NA 513 383 507 619
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 16 10 12 14
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 40 53 35 38
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 40 62
Total Current Liabilities NA 55 62 88 114
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 2 3 3
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 85 93 119 146
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 888 619 618 616
Capital Surplus NA 40 26 22 17
Retained Earnings NA -499 -355 -252 -162
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 428 290 387 472
Total Liabilities & Shareholder's Equity NA 513 383 507 619
Total Common Equity 0 428 290 387 472
Shares Outstanding 81.60 80.20 68.30 68.30 68.20
Book Value Per Share 0.00 5.34 4.25 5.67 6.92